Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-08-16
2005-08-16
Morris, Patricia L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S236000
Reexamination Certificate
active
06930120
ABSTRACT:
Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: n is 2, 3, or 4 and W is CH2, CH(OH), C(O) or O; R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aryl-alkyl, heteroaryl-alkyl, cycloalkyl-alkyl, or t-butyl; R2 is H, alkyl, haloalkyl or phenyl; Y is an unsubstituted or substituted thiophen-2,5-diyl or phenylene; R3 is alkyl or haloalkyl; R4 is a substituted or unsubstituted phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, quinolyl, pyridyl or benzo[1,3]dioxol-5-yl group; and R5 is H, alkyl, or aminoalkyl; are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.
REFERENCES:
patent: 5089514 (1992-02-01), Hulin
patent: 5232945 (1993-08-01), Hulin
patent: 5306726 (1994-04-01), Hulin
patent: 5902726 (1999-05-01), Kliewer et al.
patent: 5994554 (1999-11-01), Kliewer et al.
patent: 6294580 (2001-09-01), Willson et al.
patent: 0 930 229 (1999-07-01), None
patent: 2 359 082 (2001-08-01), None
patent: WO 97 28115 (1997-08-01), None
patent: WO 97 31907 (1997-09-01), None
patent: WO 99 46232 (1999-09-01), None
patent: WO 01 16120 (2001-03-01), None
patent: WO 02 16332 (2002-02-01), None
patent: WO 02 18355 (2002-03-01), None
Collins et al., “N-(2-Benzoylphenyl)-L-tyrosine, etc.,” J Med. Chem. 1998, 41, 5037-5054.
Sarges, R., et al.: “Glucose Transport-Enhancing and Hypoglycemic Activity of 2-Methyl-2-Phenoxy-3-Phenylpropanoic Acids”; Journal of Medicinal Chemistry, vol. 39, No. 24, Nov. 22, 1996, pp. 4783-4803.
Cobb, J. E., et al.: “N-(2-Benzoylphenyl)-L-Tyrosine PPARGamma Agonists. 3, Structure-Activity Relationship and Optimization of the N-Aryl Substituent”; Journal of Medicinal Chemistry, vol. 41, No. 25, Dec. 3, 1998, pp. 5055-5069.
Bright, S.W., et al.: “Competitve Particle Concentration Fluorescence Immunassays for Measuring Anti-Diabetic Drug Levels in Mouse Plasma”; Journal of Immunological Methods, vol. 201, No. 1, Aug. 22, 1997, pp. 23-31.
Brooks, D., et al.: “Design and Synthesis of 2-methyl-2-(4-′2-′5-methyl-2-arylaxatyl)ethoxylpropionic acids: A New Class of Dual PPARAlpha/Gamma Agonists”; Journal of Medicinal Chemistry, vol. 44, No. 13, Jun. 21, 2001, pp. 2061-2064.
Shinkai, H. et al.: “Isoxazolidine-3,5-dione and Noncyclic 1,3-dicarbonyl Compounds as Hypoglycemic Agents”; Journal of Medicinal Chemistry, vol. 41, No. 11, May 21, 1998, pp. 1927-1933.
Murugesan, N., et al.: “Biphenylsulfonamide Endothelin Receptor Antagonists 2, Discovery of 4′-oxazoly-Ibiphenylsulfonomides as a New Class of Poent, Highly Selective ET(A)Antagonists”; Journal of Medicinal Chemistry, vol. 43, No. 16, Aug. 10, 2000, pp. 3111-3117.
Malamas, M.S., et al.: “Azole Phenoxy Hydraxyureas as Selective and Orally Active Inhibitors fo 5-Lipoxygenase”; Journal of Medicinal Chemistry, vol. 39, No. 1, Jan. 5, 1996, pp. 237-245.
Merguro, K., et al.: “Studies on Antidiabetic Agents. VII. Synthesis and Hypoglycemic Avtivity fo 4-Oxazoleacetic Acid Derivatives”; Chemical & Pharmaceutuical Bulletin, vol. 34, No. 7, 1986, pp. 2840-2851.
Brooks Dawn Alisa
Godfrey Alexander Glenn
Jones Sarah Beth
McCarthy James Ray
Rito Christopher John
Eli Lilly and Company
Jang Soonhee
Morris Patricia L.
LandOfFree
Oxazolyl-arylproplonic acid derivatives and their use as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oxazolyl-arylproplonic acid derivatives and their use as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oxazolyl-arylproplonic acid derivatives and their use as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3516646